FDA spanks Celltrion South Korean biosimilars plant with warning letter

When Celltrion received an FDA Form 483 last fall for the plant where it produces Pfizer’s biosimilars, the South Korean company shrugged it off by saying it was routine. But that routine citation has now been elevated by the FDA to a warning letter.Original Article